NCT00255359View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers

PHASE1WithdrawnINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

February 28, 2006

Study Completion Date

November 30, 2007

Conditions

Chronic Hepatitis C Virus Infection

Interventions

DRUG

XTL-2125

Trial Locations (1)

91120

Hadassah Medical Organization, Jerusalem

Sponsors

Collaborators (1)

XTL Biopharmaceuticals

All Listed Sponsors

collaborator

XTL Biopharmaceuticals

INDUSTRY

lead

Hadassah Medical Organization

OTHER